APA (7th ed.) Citation

Wong, S. W., Yang, Y., Chen, H., Xie, L., Shen, X., Zhang, N., & Wu, J. (2025). New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024. Acta Pharmacologica Sinica, 46(5), 1145-1155. https://doi.org/10.1038/s41401-024-01466-7

Chicago Style (17th ed.) Citation

Wong, Shu Wei, Yong-yu Yang, Hui Chen, Li Xie, Xi-zhong Shen, Ning-ping Zhang, and Jian Wu. "New Advances in Novel Pharmacotherapeutic Candidates for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH) Between 2022 and 2024." Acta Pharmacologica Sinica 46, no. 5 (2025): 1145-1155. https://doi.org/10.1038/s41401-024-01466-7.

MLA (9th ed.) Citation

Wong, Shu Wei, et al. "New Advances in Novel Pharmacotherapeutic Candidates for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH) Between 2022 and 2024." Acta Pharmacologica Sinica, vol. 46, no. 5, 2025, pp. 1145-1155, https://doi.org/10.1038/s41401-024-01466-7.